Latest news and press releases about Anavex Life Sciences Corp. (AVXL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome.
Price
| Price | $2.36 |
| Market Cap | $219M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.92 |
| EV / EBITDA | -5.71 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -21.11% |
| Return on Invested Capital | -27.25% |
| Return on Assets | -20.01% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABSI · ARVN · ATXS · CTMX · ERAS · MBX · MGTX
Explore sector: Healthcare · Biotechnology
More sections of AVXL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks